Clinical Trials
18 trialsNCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT04635852 2020-11-19
EFFENDYS
University of Cologne
Phase 2 Completed
NCT00293033 2019-11-18
Study of BEMAâ„¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
BioDelivery Sciences International
Phase 3 Completed
NCT01516684 2019-09-06
Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
Wake Forest University Health Sciences
Phase 2 Completed
NCT01946555 2016-04-14
RER
Mario Negri Institute for Pharmacological Research
Completed
NCT01809106 2015-12-24
CERP
Mario Negri Institute for Pharmacological Research
Phase 4 Completed
NCT01248611 2014-05-12
NFCP1-2010
St. Olavs Hospital
Phase 1/2 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00236093 2014-05-09
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00458510 2013-07-11
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Archimedes Development Ltd
Phase 3 Completed
NCT00644787 2013-06-13
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 2/3 Completed
NCT00641667 2013-06-07
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00355628 2012-08-31
Clinical Study of KW-2246 in Patients With Cancer Pain
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00345735 2012-05-07
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Nycomed
Phase 2 Completed
NCT00362583 2012-05-07
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Nycomed
Phase 3 Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00589823 2010-01-22
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed